Jinxin Fertility Group Ltd. (HK:1951)
:1951
Want to see HK:1951 full AI Analyst Report?
1951 Stock Chart & Stats
HK$2.48
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$2.48
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$2.05 - HK$3.70
Previous CloseN/A
Volume13.42M
Average Volume (3M)20.30M
Market Cap
HK$5.68B
Enterprise ValueHK$6.77B
Total Cash (Recent Filing)HK$906.17M
Total Debt (Recent Filing)HK$2.96B
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Sep 01, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend Yield2.38%
Share Statistics
EPS (TTM)-0.36
Shares Outstanding2,705,044,000
10 Day Avg. Volume21,878,483
30 Day Avg. Volume20,304,545
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.64
Price to Sales (P/S)2.27
P/FCF Ratio26.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.19Price Target Upside28.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$2.85B
Bulls Say, Bears Say
Bulls Say
Manageable LeverageDebt-to-equity near 0.25–0.32 and an improving leverage trend provide durable financial flexibility. A conservative capital structure allows the company to fund clinic operations, targeted investments or M&A, and absorb cyclical headwinds without forcing near-term dilutive financing.
Operating Cash Flow ResilienceConsistent positive operating cash flow—even in the loss-making 2025 year—shows the core clinic business converts patient revenue into cash. That durability supports working capital, funding of maintenance capex, and gives management time to restore profitability without immediate liquidity stress.
High EBITDA Margins And Service ModelA ~21% EBITDA margin reflects a high‑margin assisted‑reproduction service model and operational scalability across clinics. Coupled with a networked clinical footprint, this structural margin advantage supports long‑term profitability upside if demand stabilizes and fixed costs are efficiently leveraged.
Bears Say
Revenue ContractionA shift from prior rapid expansion to negative revenue growth signals structural demand or competitive pressures. Sustained top-line weakness reduces ability to leverage fixed costs, slows patient-base expansion, and makes margin recovery harder without clear drivers for renewed organic growth.
Sharp Earnings DeteriorationA swing to a deep net loss and negative margins materially erodes retained earnings and stakeholder confidence. Over the medium term this impairs reinvestment capacity, increases scrutiny on cost structure and strategy, and may constrain hiring, marketing or clinic investments needed to restore growth.
Weakening Free Cash Flow DynamicsVolatile and declining free cash flow reduces long‑term financial flexibility. Repeated swings to negative FCF limit the company's ability to self‑fund expansion or cushion profit recovery, increasing reliance on external capital or cost cuts that can harm service capacity and long‑term competitiveness.
Jinxin Fertility Group Ltd. News
1951 FAQ
What was Jinxin Fertility Group Ltd.’s price range in the past 12 months?
Jinxin Fertility Group Ltd. lowest stock price was HK$2.05 and its highest was HK$3.70 in the past 12 months.
What is Jinxin Fertility Group Ltd.’s market cap?
Jinxin Fertility Group Ltd.’s market cap is HK$5.68B.
When is Jinxin Fertility Group Ltd.’s upcoming earnings report date?
Jinxin Fertility Group Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 74 days.
How were Jinxin Fertility Group Ltd.’s earnings last quarter?
Jinxin Fertility Group Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.034 earnings per share for the quarter, the consensus estimate of HK$0.034 by HK$0.
Is Jinxin Fertility Group Ltd. overvalued?
According to Wall Street analysts Jinxin Fertility Group Ltd.’s price is currently Undervalued.
Does Jinxin Fertility Group Ltd. pay dividends?
Jinxin Fertility Group Ltd. pays a Annually dividend of HK$0.042 which represents an annual dividend yield of 2.38%. See more information on Jinxin Fertility Group Ltd. dividends here
What is Jinxin Fertility Group Ltd.’s EPS estimate?
Jinxin Fertility Group Ltd.’s EPS estimate is 0.03.
How many shares outstanding does Jinxin Fertility Group Ltd. have?
Jinxin Fertility Group Ltd. has 2,705,044,000 shares outstanding.
What happened to Jinxin Fertility Group Ltd.’s price movement after its last earnings report?
Jinxin Fertility Group Ltd. reported an EPS of HK$0.034 in its last earnings report, expectations of HK$0.034. Following the earnings report the stock price went up 2.715%.
Which hedge fund is a major shareholder of Jinxin Fertility Group Ltd.?
Currently, no hedge funds are holding shares in HK:1951
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jinxin Fertility Group Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.67%
12-Months-Change
Fundamentals
Return on Equity
-10.66%
Trailing 12-Months
Asset Growth
-2.46%
Trailing 12-Months
Company Description
Jinxin Fertility Group Ltd.
Jinxin Fertility Group Limited is an investment holding company that specializes in providing assisted reproductive services (ARS) across both China and the United States. Its core offerings primarily include two types of treatment: artificial insemination, which can be performed using either the husband's or a donor's sperm, and advanced in vitro fertilization (IVF) technologies, ranging from conventional IVF with embryo transfer to IVF utilizing intracytoplasmic sperm injection (ICSI). To complement its ARS treatments, the company also furnishes a range of supportive services such as nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Beyond fertility-specific care, Jinxin Fertility Group extends its operations to include management services, general medical care encompassing gynecology, urology, and internal medicine, as well as ambulatory surgery center facilities and other ancillary medical services. Furthermore, the company conducts pre-implantation genetic screening tests. Its business scope also diversifies into investment management, management consulting, and real estate development and operation. Jinxin Fertility Group Limited was established in 2003 and has its corporate headquarters located in Chengdu, China.
1951 Stock 12 Month Forecast
Average Price Target
HK$3.19
▲(28.70% Upside)
Technical Analysis
Aidigong Maternal & Child Health
―
Kindstar Globalgene Technology, Inc.
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Concord Healthcare Group Co., Ltd. Class H
―
Options Prices
Currently, No data available
---